Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Meningiomas and their principal cells of origin, the arachnoidal "cap" cells are unique in their morphology with multiple and sometimes seemingly contradictory features related to their origins and basic character. Some meningiomas express mesenchymal features either in histologic pattern (fibroblastic, lipo-myxochondro-osteoblastic differentiation), participation in other disease processes, e.g. taking part in the formation of rheumatoid nodules, or in storage phenomena shared with other mesenchymal cells of the body. At the same time they may display epithelial features, such as well-formed desmosomes ultrastructurally, papillary formations and intracellular lumina in cells that stain positively for various cell markers usually considered to characterize epithelial cells. Histologic similarities of meningiomas to various gliomas, schwannomas, neuroblastomas, fibrous histiocytomas, myxomas, chordomas, metastatic carcinomas, and in the cases of meningiomas with marked inflammatory infiltrates, to benign or malignant lymphoproliferative disorders involving the meninges may pose serious diagnostic problems. The localization and resectability of meningiomas are important factors related to long-term prognosis. Of the histologic features hemangiopericytomatous pattern, papillary formations, high cellularity (focal or diffuse) and invasion of the brain appear to correlate with potentially aggressive behavior, whereas cytologically aneuploidia, large number of mitoses, prominent nucleoli and cell necrosis suggest a guarded prognosis. However, some meningiomas with no detectable histologic features of malignancy may nevertheless metastasize to distant sites.
 ...
PMID:Presidential address: the histopathology of meningiomas. A reflection of origins and expected behavior? 300 18

We report the results of a phase I study of the tolerance and biologic activity of intramuscularly (IM)-administered recombinant interferon-gamma (rIFN-gamma). Forty-four patients with metastatic cancer were given rIFN-gamma at doses ranging from 0.01 to 2.5 mg/m2/d for 42 days. The most common side effects were fever, flulike symptoms, night sweats, and granulocytopenia. The maximum tolerated dose was 0.5 mg/m2/d. Administration of rIFN-gamma resulted in modulation of immune system functions, including induction of major histocompatibility complex-associated antigens on blood leukocytes, an increase in blood surface immunoglobulin-bearing B cell and natural killer (NK) cell number, and NK cell cytotoxicity. Serum lysozyme, determined as an estimate of tissue macrophage activity, also increased. Serum assays for anti-interferon antibodies were negative in all patients. Five of eight evaluable patients with lymphoproliferative disorders showed objective evidence of tumor regression consisting of partial responses (two patients), and minor responses (three patients). These data suggest that further phase II studies of IM-administered rIFN-gamma are indicated.
 ...
PMID:Phase I study of multiple dose intramuscularly administered recombinant gamma interferon. 308 21

Secondary malignancies after marrow transplantation have been observed in 20 patients: 19 patients underwent marrow transplantation for the treatment of a hemopoietic malignancy and one for aplastic anemia. All but three were given total body irradiation at doses of 8.0-15.75 Gy as part of the conditioning regimen. Secondary malignancies were composed of three groups: (a) Six patients had recurrence of leukemia (three acute lymphoblastic, two acute myeloblastic, and one chronic myelocytic) in cells of donor origin 62-1074 days after grafting. (b) Eight patients developed lymphoproliferative disorders (four of immunoblastic sarcoma type, one lymphoblastic, one follicular center cell, and one Hodgkin's lymphoma and one acute lymphoblastic leukemia) 54-730 days after grafting. In four of seven patients with appropriate studies these tumors were of donor-cell origin and in three of four tested the cells contained Epstein-Barr virus genome or expressed viral antigens. (c) Six patients developed solid tumors (two glioblastoma multiforme, two adenocarcinomas, one squamous cell carcinoma, and one sarcoma) 347-1875 days after grafting. All but two patients (one with glioblastoma and one with squamous cell carcinoma) have died. These data suggest that patients undergoing marrow transplantation for a hemopoietic malignancy may be at risk of developing secondary malignancies. The etiology appears to be multifactorial, including irradiation, immunosuppression, Epstein-Barr virus infections, and other factors.
 ...
PMID:Secondary malignancies after marrow transplantation. 638 5

Intracytoplasmic lysozyme was studied by the peroxidase antiperoxidase (PAP) and protein A-peroxidase methods in 130 cases of various myeloproliferative and lymphoproliferative disorders and 21 lymph nodes and bone marrow metastases from solid primary tumors. This marker, which can be identified in formalin or Zenker-fixed tissues, as well as in peripheral blood and bone marrow smears, proved useful to distinguish malignant myeloid and histiocytic tumors from malignant lymphoid and undifferentiated epithelial metastases. The diagnostic application of these findings are discussed.
 ...
PMID:Intracytoplasmic lysozyme in malignant hematologic disorders: an immunoperoxidase study. 675 56

A supportive or causal role for human herpesvirus 6 (HHV-6) in lymphoproliferative disorders is still controversial. Different results were obtained in both tissue-based and serological investigations. We investigated 243 lymph node and salivary gland tissue biopsies for the presence of viral DNA by using a newly developed, highly sensitive nested polymerase chain reaction method. HHV-6 was detected in 39% of the non-Hodgkin's lymphomas, in 52% of Hodgkin's diseases, 64% of non-neoplastic lymph nodes, 23% of tumor metastases, and 50% of salivary gland biopsies. When correlating the patients' ages with the occurrence of HHV-6, we found a significantly higher percentage of positive samples in patients younger than 60 years of age (54%) than in older patients (35%). This age-related difference was found in all the lymphoproliferative disorders studied as well as in salivary gland biopsies. Taking patient's ages into account, we found no significant difference between the various groups of disorders concerning the percentage of HHV-6-positive samples.
 ...
PMID:Presence of human herpesvirus type 6 in sporadic lymphoproliferative disorders. A comparative study. 886 29

The aim of this review is to explore some of the major ways in which the techniques of molecular biology are affecting individual patient diagnosis with respect to lymphoproliferative disorders. The main impact in this particular sphere has been through the polymerase chain reaction which has enabled clonal analysis, the detection of diagnostically and prognostically important chromosomal abnormalities and the monitoring of therapeutic intervention via the detection of residual disease. This allows increased diagnostic accuracy and enables better targeting of therapeutic intervention. A younger technology, but none the less one with great diagnostic potential, is that of fluorescence in situ hybridisation which has bridged the gap between conventional cytogenetics, with its reliance on living tissues and its relative insensitivity in picking up chromosomal abnormalities, and molecular biology which forsakes morphology and which, in the shape of PCR at least, deals with relatively minute segments of the genome. The main techniques of clonal analysis are compared and contrasted and the usefulness of the detection of some of the major chromosomal abnormalities is discussed. The place of fluorescence in situ hybridisation is also elaborated. The major advantages and disadvantages of each of these techniques are described and their place in the scheme of diagnosis and treatment is briefly elucidated.
Cancer Metastasis Rev 1997 Jun
PMID:Molecular diagnosis of lymphomas and associated diseases. 915 82

CD30+ large anaplastic lymphoid cells are seen in anaplastic large cell lymphoma (ALCL), and also in lymphomatoid papulosis (LyP) and other lymphoproliferative disorders. It can be difficult precisely to categorize these disorders with CD30+ cells. We report a case of primary cutaneous CD30+ ALCL with systemic metastases in whom the clinical disease subsequently evolved into LyP. The patient was initially administered cisplatin and etoposide and made a good response. Eighteen months later, recurrent, self-healing cutaneous small nodules appeared around the original tumour site without any systemic involvement. Histopathological examination of the recurrent lesions revealed infiltration with a mixture of cells that included neutrophils, eosinophils and CD30+ large anaplastic cells cytologically identical with those in the primary lesion. The anaplastic cells in both the primary and recurrent lesions were positive for monoclonal antibodies CD30, CD25 and a monoclonal antibody directed against the chimeric protein p80(NPM-ALK). These observations suggest the possibility that the ALCL and the subsequent LyP represent different clinical manifestations of proliferation of the same clone.
 ...
PMID:CD30+ lymphoproliferative disorder: primary cutaneous anaplastic large cell lymphoma followed by lymphomatoid papulosis. 1145 20

Paraneoplastic syndromes are manifestations of malignancies that have produced effects that are distant from the primary tumor or metastases. Paraneoplastic syndromes are not caused by local effects of compression or infiltration into tissues, but are generally due to ectopic hormone production, autoimmune phenomena, or overproduction of cytokines. Paraneoplasia may be the presenting symptom of underlying malignancy and can affect almost any organ system, such as the neurologic syndromes associated with small-cell lung cancer or hypercalcemia associated with squamous cell carcinomas. Lymphoproliferative disorders are also associated with many paraneoplastic disorders; however, to date, most published information has been in the form of case reports and series of small numbers of patients. In this review, the most common paraneoplastic syndromes associated with non-Hodgkin's lymphoma and Hodgkin's disease will be discussed.
 ...
PMID:Paraneoplastic manifestations of lymphoma. 1524 5

Basal cell carcinoma (BCC) is usually a benign and indolent cancer cured in greater than 95 percent of cases. Nevertheless, it can be locally destructive or occasionally metastasize to distant organs. We report a case of BCC metastatic to the lungs, occurring 17 years after the primary BCC was noticed, that responded to carboplatin and paclitaxel on 3 occasions. The patient also developed pure red cell aplasia (PRCA). Work-up did not reveal underlying thymoma or infectious, rheumatologic, or lymphoproliferative disorders. Parvovirus serologies were negative, and antibodies against erythropoetin were not detected. There was no history of exposure to drugs associated with PRCA. Bone marrow biopsy on 2 different occasions did not show evidence of myelodysplasia. PRCA may represent an unusual paraneoplastic syndrome associated with BCC as reported with other carcinomas. This is the first report of PRCA associated with metastatic BCC or the drugs carboplatin and paclitaxel, which were used to treat it. The literature on chemotherapy for metastatic BCC is reviewed.
 ...
PMID:Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. 1677 92

Paraneoplastic symptoms, caused by a malignancy, but not directly related to invasion by the tumor or its metastases are the result of a wide variety of tumor-derived biologic mediators like hormones, peptides, antibodies, cytotoxic lymphocytes, autocrine and paracrine mediators. Recognition of paraneoplastic syndromes is important, as it may lead to an early diagnosis of cancer. There is some evidence that systemic inflammatory diseases, such as rheumatoid arthritis (RA), lupus, scleroderma or dermatomyositis may increase the risk for the development of malignancies, predominantly lymphoproliferative disorders. However, reports are somewhat controversial. Immunosuppressive and cytotoxic drugs used in antirheumatic therapy, such as methotrexate, cyclophosphamide, azathioprine or anti-TNF biologicals may also lead to the development of such tumors. Tumor-associated antigens may be produced by inflammatory cells and their production may be increased in RA and other autoimmune diseases.
 ...
PMID:Malignancies and soluble tumor antigens in rheumatic diseases. 1711 Mar 16


1 2 Next >>